Institution
Novadip (Belgium)
BEcompany
Recent research
- Open access
Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E6...